Key result
Cerebrovascular MRI biomarkers emerge by age 50 and track with Alzheimer progression in Down syndrome.
Cross-Sectional (n=138)
Answers are grounded in this paper and cite their sources.
OBJECTIVE: Adults with Down syndrome (DS) develop Alzheimer disease (AD) pathology by their 5th decade. Compared with the general population, traditional vascular risks in adults with DS are rare, allowing examination of cerebrovascular disease in this population and insight into its role in AD without the confound of vascular risk factors. We examined in vivo magnetic resonance imaging (MRI)-based biomarkers of cerebrovascular pathology in adults with DS, and determined their cross-sectional relationship with age, beta-amyloid pathology, and mild cognitive impairment or clinical AD diagnostic status. METHODS: Participants from the Biomarkers of Alzheimer's Disease in Down Syndrome study (n = 138, 50 ± 7 years, 39% women) with MRI data and a subset (n = 90) with amyloid positron emission tomography (PET) were included. We derived MRI-based biomarkers of cerebrovascular pathology, including white matter hyperintensities (WMH), infarcts, cerebral microbleeds, and enlarged perivascular spaces (PVS), as well as PET-based biomarkers of amyloid burden. Participants were characterized as cognitively stable (CS), mild cognitive impairment-DS (MCI-DS), possible AD dementia, or definite AD dementia based on in-depth assessments of cognition, function, and health status. RESULTS: There were detectable WMH, enlarged PVS, infarcts, and microbleeds as early as the 5th decade of life. There was a monotonic increase in WMH volume, enlarged PVS, and presence of infarcts across diagnostic groups (CS < MCI-DS < possible AD dementia < definite AD dementia). Higher amyloid burden was associated with a higher likelihood of an infarct. INTERPRETATION: The findings highlight the prevalence of cerebrovascular disease in adults with DS and add to a growing body of evidence that implicates cerebrovascular disease as a core feature of AD and not simply a comorbidity. ANN NEUROL 2020;88:1165-1177.
No takes yet. Share an insight, caveat, or question.
Lao et al. (2020) conducted a cross-sectional in Down syndrome and Alzheimer disease (n=138). Age, beta-amyloid pathology, and clinical AD diagnostic status vs. Cognitively stable status was evaluated on MRI-based biomarkers of cerebrovascular pathology (white matter hyperintensities, infarcts, cerebral microbleeds, and enlarged perivascular spaces). In 138 adults with Down syndrome (mean age 50 years), MRI cerebrovascular biomarkers were detectable by the 5th decade and increased across AD diagnostic groups.
Synapse has enriched 10 related papers. Consider them for comparative context: